"Protective Effects of a Live Attenuated SIV Vaccine With a Deletion in" the Nef Gene

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

"Protective Effects of a Live Attenuated SIV Vaccine With a Deletion in" the Nef Gene

Science (12/18/92) Vol. 258, No. 5090, P. 1939
Daniel, Muthiah et al.

Abstract: Live attenuated HIV-1 may also be the most potent, effective vaccine for the prevention of AIDS, write Muthiah D. Daniel et al. of the New England Regional Primate Research Center, Harvard Medical School, in Southborough, Mass. Vaccine protection against HIV and simian immunodeficiency virus (SIV) in animal models is proving to be a difficult task. The problem is largely attributable to the persistent, unrelenting nature of HIV and SIV infection once infection is initiated. SIV with a constructed deletion in the auxillary gene nef replicates poorly in rhesus monkeys and appears to be nonpathogenic in this normally susceptible host. Rhesus monkeys vaccinated with live SIV deleted in nef were completely protected against challenge by intravenous inoculation of live, pathogenic SIV. Concern for safety is likely to be the main issue for the eventual development of the deletion approach. In addition to nef, other genetic elements can be deleted from HIV-1 to help guarantee long-term safety. The use of deletion mutants eliminates the possibility of reversion and helps to guarantee the safety of inoculation with the attenuated virus. Deletion of nef or of multiple genetic elements from HIV may provide the means for creating a safe, effective live attenuated vaccine to protect against AIDS, conclude the researchers.

921218
AD922527

Copyright © 1992 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.